Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.
DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.
DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.
Download Results (CSV)
|
Download Full Data Set (XLS)
| Condition |
Intervention
|
Intervention type
|
Intervention description |
Intervention setting
|
Objective
|
Target population
|
Cost effectiveness
(US$/DALY)
|
Cost effectiveness estimate
(US$)
|
Cost effectiveness range
(US$/DALY)
|
Number of DALYs averted
(hundreds)
|
Number of deaths averted
(hundreds)
|
Quality of cost-effectiveness analysis evidence
|
|
Osteoporosis
|
Calcium supplements with or without vitamin D |
Personal |
Calcium with or withouth vitamin D supplements, based on evidence that it reduces appendicular fractures; assumes a compliance rate of 70% |
Clinic
|
primary prevention
|
Adults
|
- |
37,633-149,705 per QALY |
- |
- |
- |
1 |
|
Osteoporosis
|
Fluoride |
Personal |
Fluoride appears to decrease the risk of vertebral fracture for women with established osteoporosis; assumes neutral effect on hip fractures |
Clinic
|
secondary prevention
|
Adults
|
- |
46,684 per QALY (UK) |
- |
- |
- |
1 |
|
Osteoporosis
|
Hormone replacement therapy |
Personal |
Estrogen replacement from age 50, 60, or menopause for healthy women; 5-year to lifetime treatment |
Clinic
|
primary prevention, secondary prevention
|
Adults
|
- |
5088-23,734 per QALY |
- |
- |
- |
1 |
|
Osteoarthritis
|
Lifestyle change |
Personal |
Exercise (aquatic) and calcium supplements |
Clinic
|
primary prevention, secondary prevention
|
Adults
|
- |
96,119-498,700 per QALY (Highincome countries) |
- |
- |
- |
1 |
|
Osteoporosis
|
Nonestrogen drug treatments |
Personal |
Raloxifene or calcitonin to reduce bone fractures; with or without 5 years of therapy |
Clinic
|
secondary prevention
|
Adults
|
- |
34,166-835,622 per QALY (High income Countries) |
- |
- |
- |
1 |
|
Osteoarthritis
|
Replacement surgery |
Personal |
Synovial fluid replacement (hylan G-F 20) for patients with osteoarthritis of the knee; or complete hip joint or knee replacement with implant |
Clinic, Local or district hospital
|
secondary prevention
|
Adults
|
5233-6893 per QALY (High income countries) |
Elderly men and women |
- |
- |
- |
- |
Download Results (CSV)
|
Download Full Data Set (XLS)